AI assistant
IDEXX LABORATORIES INC /DE — Director's Dealing 2012
Nov 28, 2012
30016_dirs_2012-11-28_fd2a25a9-bcdc-41fd-bfdc-9e1b07caf0cf.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2012-11-27
Reporting Person: AYERS JONATHAN W (Director, Chairman, President & CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2012-11-27 | Common Stock | M | 20000 | $17.1350 | Acquired | 393133 | Direct |
| 2012-11-27 | Common Stock | S | 13000 | $92.4966 | Disposed | 380133 | Direct |
| 2012-11-27 | Common Stock | S | 2000 | $93.8064 | Disposed | 378133 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2012-11-27 | Non-Qualified Stock Option (right to buy) | $17.135 | M | 20000 | Disposed | 2013-02-06 | Common Stock (20000) | Direct |
Footnotes
F1: The sale reported above was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 04/27/2012.
F2: The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $92.26 to $93.18, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.
F3: The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $93.47 to $94.06, inclusive.
F4: Grant of options to buy shares of common stock becomes exercisable as to 30,000 shares on 02/06/2004, 02/06/2005, 02/06/2006, and 02/06/2007, and the remaining 24,164 shares on 02/06/2008.